Donanemab in Early Symptomatic Alzheimer Disease - JAMA Network
Jul 17, 2023 · This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody …
Donanemab in Early Symptomatic Alzheimer Disease: The ... - PubMed
Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque.
Donanemab in early symptomatic Alzheimer’s disease: results from the ...
Feb 1, 2026 · In the pivotal phase 3 TRAILBLAZER-ALZ 2 trial, donanemab significantly slowed clinical progression compared with …
Donanemab in Early Symptomatic Alzheimer Disease: The …
Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque.
Donanemab in Early Alzheimer’s Disease - The New England Journal …
Mar 13, 2021 · We conducted a phase 2 trial of donanemab in patients with early symptomatic Alzheimer’s disease who had tau and …
Donanemab in Early Symptomatic Alzheimer Disease: The …
Aug 1, 2023 · There are limited efficacious treatments for Alzheimer disease. To assess efficacy and adverse events of donanemab, …
Donanemab in Early Symptomatic Alzheimer Disease: The
Jul 17, 2023 · Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque.
Donanemab in early symptomatic Alzheimer’s disease
Overview of: Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 …
Use of Donanemab in Early Symptomatic Alzheimer Disease—Reply | JAMA …
Dec 19, 2023 · In Reply Amyloid-related imaging abnormalities are a common adverse event for individuals with Alzheimer disease …
Donanemab in Early Symptomatic Alzheimer Disease: The
Aug 8, 2023 · There are limited efficacious treatments for Alzheimer disease.